论文信息 - Monitoring accumulating data in a clinical trial.

Monitoring accumulating data in a clinical trial.

A clinical trial is monitored for efficacy or safety; the variable of interest is death or a similarly serious event. The probability that one therapy has a greater mortality rate than the other is calculated ad libitum during the trial. Adjustments are made for differing patients' prognoses and for survival times.

D. Berry

[1] N. L. Johnson,et al. Survival Models and Data Analysis , 1982 .

[2] R. G. Cornell,et al. National experience with extracorporeal membrane oxygenation for newborn respiratory failure. Data from 715 cases. , 1988, ASAIO transactions.

[3] Ward Edwards,et al. Bayesian statistical inference for psychological research. , 1963 .

[4] James O. Berger,et al. The Relevance of Stopping Rules in Statistical Inference , 1988 .

[5] J. Ware. Investigating Therapies of Potentially Great Benefit: ECMO , 1989 .

[6] J. Goyan. Drug regulation: quo vadis? , 1988, JAMA.

[7] R. G. Cornell,et al. Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. , 1985, Pediatrics.

[8] D. Spiegelhalter,et al. A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. , 1986, Statistics in medicine.

[9] D A Berry,et al. One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach. , 1988, Biometrics.

[10] Donald A. Berry,et al. Bandit Problems: Sequential Allocation of Experiments. , 1986 .

[11] Donald A. Berry,et al. Interim analysis in clinical trials; the role of the likelihood principle , 1987 .

[12] K. Chaloner,et al. Assessment of a Beta Prior Distribution: PM Elicitation , 1983 .

[13] W. Dupont. Sequential stopping rules and sequentially adjusted P values: does one require the other? , 1983, Controlled clinical trials.